FDA

Dear Research Advocate: As you know, there has been a cease fire in the shutdown and people are back to work, at least for now. Over the next two weeks, members of Congress will attempt to resolve the stalemate over funding for the President’s border wall, packaging it with the seven remaining FY 2019 spending bills, which include funding for the Food and Drug Administration (FDA) and the National Science Foundation (NSF). I am feeling optimistic about a deal being struck, not least because Sen. Richard Shelby (R-AL), Chairman of the Senate Appropriations Committee, and Representative Nita Lowey (D-NY), Chairwoman of the House Appropriations Committee, are leading the congressional...
Dear Research Advocate, The partial government shutdown continues, now at day 27. There are too many furloughed workers struggling to make ends meet, our nation’s parks and monuments are being ruined, research support by NSF has been put on hold, and drug approvals have slowed at FDA. For a run-down on the broadscale impact, see this USA Today article quoting ASBMB’s Ben Corb, and for a closer look at the toll the shutdown is taking on research, check out this article discussing the impact at the University of Wisconsin, emblematic of so many campuses nationwide. As a temporary patch, agency leaders have called back thousands of employees to work without pay. At the FDA, Commissioner Scott...
Dear Research Advocate: The government remains in a partial shutdown that began on December 22, taking a mounting toll on 800,000 federal workers, including those at FDA and NSF. The Alliance for a Stronger FDA has put together a “ Shutdown Toolkit ” detailing how this ongoing impasse is affecting us all. In a similar vein, the Coalition for National Science Funding has been sharing stories on social media that focus on how the shutdown is impacting NSF-funded research and programs, stifling discovery and sending a message of ‘no public confidence’ to aspiring young scientists. Clearly, the effects of the shutdown on research are multiple, disruptive and counterproductive. This New York...
Dear Research Advocate: At our post-election briefing this morning at AAAS in Washington, DC, the discussion focused on opportunities for advocacy given the composition and characteristics of the new Congress, and the importance of building new champions from among the nearly 100 new members of Congress. Of note — at last count, there are seven science-trained new members, a very welcome development! There is no doubt that a divided Congress can cause gridlock, but inaction is not a foregone conclusion, as was emphasized by our Chair, the Hon. Michael N. Castle. There are important, science-relevant issues, such as infrastructure, STEM education, and the opioid crisis, that both parties...
Dear Research Advocate: Earlier today, Rob Smith and Kim Monk of Capital Alpha Partners, and Pete Kirkham of Red Maple Consulting joined Research!America alliance members to discuss the near and mid-term outlook for congressional action on drug pricing, the state of play on appropriations, and other research-relevant issues. Although our speakers noted that much can change in the final week before the election, there were several key takeaways. First, it’s safe to say that the uncertainties surrounding the election and the ongoing interest (both in Congress and the White House) in addressing rising healthcare costs means that drug pricing and issues related to the supply chain more...
To Americans, there are few things more terrifying than going blind . Glaucoma is a particularly scary vision-stealing disease because without screening it offers no warning to those it strikes, causing significant, irreversible vision loss before a patient notices something is wrong. But in January, in honor of Glaucoma Awareness Month, the vision-research community reflects on the past year’s progress toward managing this challenging disease. As with all diseases, progress is dependent on research. First, it looks into understanding what causes the condition, and then into therapies that prevent, treat or cure it. Glaucoma research, spanning decades, has successfully identified what...
Research into the development of Ebola vaccines, efforts to address opioid use among women, infectious diseases and a record number of novel drug approvals are among the many examples of federal health agencies making tremendous strides in 2017 to address complex and deadly health threats. The agencies highlighted their achievements in year-end articles, videos and reports on their websites. The National Institutes of Health (NIH) described progress with two Ebola vaccines and a bionic pancreas to better treat type 1 diabetes in addition to other clinical advances. The NIH also supported the work of three recipients of the Nobel Prize in Physiology or Medicine and one recipient of the Nobel...
Dear Research Advocate: In considering resolutions for the coming year, I am reminded that resolution connotes action . I am optimistic that 2018 will be a year of action, a year in which research and innovation amp up our economy, even as they lead to better health and quality of life. Congress will respond to advocates if we all take action and amp up our efforts — it’s an election year, after all! Love it or loathe it, tax reform has set the stage for additional action to drive the economy. In addition to passing a bipartisan budget deal that lifts spending caps for both defense and non-defense discretionary funding, and repealing or suspending the medical device tax, Congress and the...
"My doctor just told me I have lung cancer… What do I do?" This is a familiar line for anyone who has spoken with a patient on Lung Cancer Alliance’s HelpLine . With a historically low survival rate and a significant stigma due to the misguided belief that it is only a “smoker’s disease,” lung cancer flies under the radar. However, no one deserves to die from any cancer, and most people don’t know that lung cancer is the number one cancer killer that will claim an estimated 160,000 lives in the U.S. this year alone. Fortunately, thanks to the power of research, the tide is turning in the fight against this disease and there's an entirely different story to tell this November during Lung...
Let’s start with this: think of each person’s cancer as a unique locked door. Now imagine that with a simple test, we could find the right key to unlock that door and cure the cancer on the first try. This is the world of precision medicine, an emerging area of research that the Prostate Cancer Foundation (PCF) feels is the mechanism for finally unlocking the cancer problem. So what does this mean for patients? Consider Mark Meerschaert’s experience. In a matter of weeks, Mark went from being an active on-the-go professor to someone who could barely walk; metastatic prostate cancer had come from nowhere and spread throughout his body. As a respected mathematics professor and researcher,...

Pages

Sidebar Quote

We have health challenges in this country that science will provide answers for if given the chance and we haven't given science that opportunity
Mary Woolley, President and CEO, Research!America